

Expand IV-to-PO Switches

Hospitals will refocus on IV-to-po protocols...due to recent data suggesting many eligible patients aren't switched to po.

IV-to-po conversions have been on our radar for years...to improve patient care, decrease workload, reduce cost, etc.

Meds with 1:1 conversions (quinolones, PPIs, etc) are frequent targets for pharmacy protocol switches. But be ready to tackle IV-to-po switches that aren't as straightforward.

Antimicrobials. Work with ID colleagues to create protocols when there's not an exact IV-to-po conversion...or culture results aren't available. Incorporate local resistance patterns.

For example, consider changing ceftriaxone for community-acquired pneumonia to an agent such as amoxicillin/clavulanate, cefdinir, or cefuroxime...once patients are hemodynamically stable and afebrile.

Use similar criteria to switch a patient with uncomplicated gram-negative bacteremia to po...if you also have susceptibility results and an identified source.

For instance, consider TMP/SMX 2 DS tabs bid for susceptible *E. coli* bacteremia from a urinary source...to complete a 7-day course.

But don't jump to po for all infections. For example, work with ID for patients with gram-positive bacteremia, especially *Staph aureus*.

Electrolytes. Adjust your prn replacement protocol for potassium to default to oral instead of IV...unless patients are symptomatic, have levels less than 2.5 mEq/L, are NPO, etc.

Also use po magnesium or phosphorus for asymptomatic patients with mildly low levels...especially during shortages of IV formulations.

But rely on IV magnesium and phosphorus for larger doses due to increased side effects with oral products. For example, giving 800 mg or more of magnesium oxide may increase diarrhea risk.

Plus absorption of oral phosphorus supplements may be unreliable.

Opioids. Create a protocol for post-op or other acute pain patients. Consider changing prn IV opioids to oral after several doses if patients meet po criteria. For example, try oxycodone 5 mg po for morphine 2 to 4 mg IV.

When identifying candidates for any IV-to-po conversion, work with your IT team to create EHR alerts or reports. And add po options to order sets with instructions for nurses to try before IV.

Don't decide that a patient is taking po based strictly on profiled meds. Look at med administration records...or check the EHR for IV lines or enteral tubes. Discuss with the nurse if needed.

Go to our resource, *Considerations for IV-to-PO Conversions*, for guidance on amiodarone, steroids, anticonvulsants, and more.

Key References:

- Engers DW, Tamma PD, Fiawoo S, et al. Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections. *JAMA Netw Open*. 2024 Jan 2;7(1):e2349864.
- Deshpande A, Klompas M, Guo N, et al. Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized With Community-Acquired Pneumonia. *Clin Infect Dis*. 2023 Jul 26;77(2):174-185.

Cite this document as follows: Article, Expand IV-to-PO Switches, Pharmacist's Letter Canada, June 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2024 Therapeutic Research Center (TRC). TRC and Pharmacist's Letter Canada and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.

-Heil EL, Bork JT, Abbo LM, et al. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. *Open Forum Infect Dis.* 2021 Oct 11;8(10):ofab434.

-Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. *Am J Health Syst Pharm.* 2005 Aug 15;62(16):1663-82.

Hospital Pharmacist's Letter. June 2024, No. 400618

Cite this document as follows: Article, Expand IV-to-PO Switches, Pharmacist's Letter Canada, June 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2024 Therapeutic Research Center (TRC). TRC and Pharmacist's Letter Canada and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.